We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn about our cookie policy.
Sigma-Aldrich Clozapine N-oxide hydrochloride. ≥98% (HPLC), powder, muscarinic DREADD activator. 5 mg
List Price $274.17 Your Price $274.17
Sigma-Aldrich Clozapine N-oxide hydrochloride. ≥98% (HPLC), powder, muscarinic DREADD activator. 5 mg - SIAL (Additional S&H Or Hazmat Fees May Apply)
NETA PART: SIAL-SML2304-5MG
MFG.PART: SML2304-5MG
UNSPSC: 12352202
Manufacturer: Sigma-Aldrich


Product Name
Clozapine N-oxide hydrochloride, ≥98% (HPLC), Water soluble Clozapine N-oxide
biological source
synthetic
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
solubility
DMSO: 40 mg/mL
water: 40 mg/mL
shipped in
ambient
storage temp.
2-8°C
SMILES string
ClC1=CC2=C(NC(C=CC=C3)=C3C(N4CC[N+]([O-])(C)CC4)=N2)C=C1.[xHCl]
InChI
1S/C18H19ClN4O/c1-23(24)10-8-22(9-11-23)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3
General description
Clozapine N-oxide hydrochloride is a water soluble form of Clozapine N-oxide (CNO) (Sigma cat# C0832). CNO is a pharmacologically inert metabolite of the atypical anti-psychotic drug clozapine. CNO is a ligand for the engineered Gq protein coupled receptors (GPCRs) in the chemogenetic Designer Receptors Exclusively Activated by Designer Drug (DREADD). The typical use of DREADD is testing, enhancing neuronal firing and activating Gq signaling in neuronal and non-neuronal cells.
The selective targeting of DREADD systems to cell population can be achieved by using a cell type-specific promoter to drive DREADD expression, and the expression of this promoter can be further controlled using a recombinase-based system. DREADDs possess a low affinity for endogenous ligands and little constitutive activity, but may be activated by synthetic compounds such as CNO.
DREADD systems are activated by low nM concentrations of CNO and mobilize intracellular calcium. CNO appears to be pharmacologically and behaviorally inert in mice and rats when administered at the recommended doses (generally 0.1–3 mg/kg). CNO is commonly administrated via injection but also can be mixed into food chow or drinking water.
The selective targeting of DREADD systems to cell population can be achieved by using a cell type-specific promoter to drive DREADD expression, and the expression of this promoter can be further controlled using a recombinase-based system. DREADDs possess a low affinity for endogenous ligands and little constitutive activity, but may be activated by synthetic compounds such as CNO.
DREADD systems are activated by low nM concentrations of CNO and mobilize intracellular calcium. CNO appears to be pharmacologically and behaviorally inert in mice and rats when administered at the recommended doses (generally 0.1–3 mg/kg). CNO is commonly administrated via injection but also can be mixed into food chow or drinking water.
Other Notes
This is not a pharmaceutical grade product.
pictograms
GHS06
signalword
Danger
hcodes
H301,H336
pcodes
P261 - P264 - P271 - P301 + P310 - P304 + P340 + P312 - P403 + P233
Hazard Classifications
Acute Tox. 3 Oral - STOT SE 3
target_organs
Central nervous system
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
| SKU | SIAL-SML2304-5MG |
|---|---|
| Supplier Part Number | SML2304-5MG |
| UM | EA |
| UNSPSC | 12352202 |
| Manufacturer | Sigma-Aldrich |
| Temperature | 2-8C |
| Refrigerated-Frozen | Y |
| ProductLine | SIAL |
| Qty | 1 |
| MinOrderQty | 1 |
| Weight | 10.000000 |
| Lead Time | 9 |
| Energy Star | No |
| Green | No |
| Controlled | N |

